Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross-over trial.


Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
11 2019
Historique:
received: 30 07 2018
revised: 26 02 2019
accepted: 16 04 2019
pubmed: 15 5 2019
medline: 30 5 2020
entrez: 15 5 2019
Statut: ppublish

Résumé

Non-invasive ventilation (NIV) is part of the standard of care for hypercapnic respiratory failure secondary to COPD, but may be poorly tolerated. Preliminary evidence suggests nasal high-flow (NHF) therapy may improve hypercapnia in COPD and be well tolerated. We compared NHF and NIV in people with COPD and chronic hypercapnic respiratory failure. Single-blind randomized controlled two-way cross-over single-centre trial was conducted in New Zealand. Twenty-four participants with stable hypercapnic COPD received: NHF at 45 L/min and NIV at 15/4 cm H NIV reduced the PtCO In stable COPD patients with chronic hypercapnia, NIV resulted in a greater reduction in PtCO ACTRN12616001701415 at www.anzctr.org.au.

Sections du résumé

BACKGROUND AND OBJECTIVE
Non-invasive ventilation (NIV) is part of the standard of care for hypercapnic respiratory failure secondary to COPD, but may be poorly tolerated. Preliminary evidence suggests nasal high-flow (NHF) therapy may improve hypercapnia in COPD and be well tolerated. We compared NHF and NIV in people with COPD and chronic hypercapnic respiratory failure.
METHODS
Single-blind randomized controlled two-way cross-over single-centre trial was conducted in New Zealand. Twenty-four participants with stable hypercapnic COPD received: NHF at 45 L/min and NIV at 15/4 cm H
RESULTS
NIV reduced the PtCO
CONCLUSION
In stable COPD patients with chronic hypercapnia, NIV resulted in a greater reduction in PtCO
CLINICAL TRIAL REGISTRATION
ACTRN12616001701415 at www.anzctr.org.au.

Identifiants

pubmed: 31083777
doi: 10.1111/resp.13575
doi:

Substances chimiques

Carbon Dioxide 142M471B3J

Banques de données

ANZCTR
['ACTRN12616001701415']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1081-1087

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Asian Pacific Society of Respirology.

Références

Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, Church AC, Creagh-Brown B, Dodd JW, Felton T et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax 2016; 71(Suppl. 2): ii1-35.
Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P Members of the Steering Committee, Antonelli M, Brozek J, Conti G et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur. Respir. J. 2017; 50: 1602426.
Murphy P, Rehal S, Arbane G, Bourke S, Calverley P, Crook A, Dowson L, Duffy N, Gibson G, Hughes P et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation. JAMA 2017; 317: 2177-86.
Köhnlein T, Windisch W, Köhler D, Drabik A, Geiseler J, Hartl S, Karg O, Laier-Groeneveld G, Nava S, Schönhofer B et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir. Med. 2014; 2: 698-705.
Carlucci A, Richard JC, Wysocki M, Lepage E, Brochard L. Noninvasive versus conventional mechanical ventilation: an epidemiologic survey. Am. J. Respir. Crit. Care Med. 2001; 163: 874-80.
Benhamou D, Girault C, Faure C, Portier F, Muir JF. Nasal mask ventilation in acute respiratory failure; experience in elderly patients. Chest 1992; 102: 912-7.
Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 2016; 71: 759-61.
Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir. Med. 2009; 103: 1400-5.
Lee JH, Rehder KJ, Williford L, Cheifetz IM, Turner DA. Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature. Intensive Care Med. 2013; 39: 247-57.
Nishimura M. High-flow nasal cannula oxygen therapy in adults. J. Intensive Care 2015; 3: 15.
Pilcher JA, Eastlake LE, Richards MI, Power S, Cripps T, Bibby S, Braithwaite I, Weatherall M, Beasley R. Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: a randomized controlled cross-over trial. Respirology 2017; 22: 1149-55.
McKinstry S, Pilcher J, Bardsley G, Berry J, Van de hei S, Braithwaite I, Fingleton J, Weatherall M, Beasley R. Nasal high flow therapy and PtCO2 in stable COPD: a randomized controlled cross-over trial. Respirology 2018; 23: 378-84.
Bräunlich J, Köhler M. Nasal highflow improves ventilation in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 1077-85.
Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013; 85: 319-25.
Bräunlich J, Mauersberger F, Wirtz H. Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent. BMC Pulm. Med. 2018; 18: 14.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten C, Gustafsson P et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-38.
Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J. Crit. Care 2012; 27: 324.e9-13.
Wijesinghe M, Williams M, Perrin K, Weatherall M, Beasley R. The effect of supplemental oxygen on hypercapnia in subjects with obesity-associated hypoventilation: a randomized, crossover, clinical study. Chest 2011; 139: 1018-24.
Vogelmeier C, Criner G, Martinez F, Anzueto A, Barnes P, Bourbeau J, Celli B, Chen R, Decramer M, Fabbri L et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Am. J. Respir. Crit. Care Med. 2017; 195: 557-82.
Zavorsky GS, Cao J, Mayo NE, Gabbay R, Murias JM. Arterial versus capillary blood gases: a meta-analysis. Respir. Physiol. Neurobiol. 2007; 155: 268-79.
Heidari K, Hatamabadi H, Ansarian N, Alavi-Moghaddam M, Amini A, Safari S, Darbandsar Mazandarani P, Vafaee A. Correlation between capillary and arterial blood gas parameters in an ED. Am. J. Emerg. Med. 2013; 31: 326-9.
Murphy R, Thethy S, Raby S, Beckley J, Terrace J, Fiddler C, Craig M, Robertson C. Capillary blood gases in acute exacerbations of COPD. Respir. Med. 2006; 100: 682-6.
Domingo C, Canturri E, Luján M, Moreno A, Espuelas H, Marín A. Transcutaneous measurement of partial pressure of carbon dioxide and oxygen saturation: validation of the SenTec monitor. Arch. Bronconeumol. 2006; 42: 246-51.
Rodriguez P, Lellouche F, Aboab J, Buisson CB, Brochard L. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adult patients. Intensive Care Med. 2006; 32: 309-12.
Storre JH, Magnet FS, Dreher M. Transcutaneous monitoring as a replacement for arterial PCO2 monitoring during nocturnal non-invasive ventilation. Respir. Med. 2011; 105: 143-50.
Fingleton J, McKinstry S, Pilcher J, Weatherall M, Beasley R, Bardsley G. Accuracy of transcutaneous carbon dioxide measurement for change over time, in TSANZ oral presentations. Respirology 2017; 22(Suppl. 2): 18-100.
Nilius G, Franke KJ, Domanski U, Ruhle KH, Kirkness JP, Schneider H. Effects of nasal insufflation on arterial gas exchange and breathing pattern in patients with chronic obstructive pulmonary disease and hypercapnic respiratory failure. Adv. Exp. Med. Biol. 2013; 755: 27-34.
Bräunlich J, Wirtz H. NHF and hypercapnia: how brief can you look? Respirology 2017; 22: 1049-50.
Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD : a randomised crossover trial. Thorax 2010; 65: 303-8.
Storgaard LH, Hockey H, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched nasal high flow treatment in COPD with chronic hypoxemic respiratory failure. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 1195-205.
Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T, Tokioka F, Chohnabayashi N, Watanabe A, Sato S et al. Domiciliary high-flow nasal cannula oxygen therapy for stable hypercapnic COPD patients: a multicenter, randomized crossover trial. Ann. Am. Thorac. Soc. 2018; 15: 432-9.
Bräunlich J, Seyfarth H-J, Wirtz H. Nasal high-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report. Multidiscip. Respir. Med. 2015; 10: 27.
Pisani L, Fasano L, Corcione N, Comellini V, Assunta Musti M, Brandao M, Bottone D, Calderini E, Navalesi P, Nava S. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax 2017; 72: 373-5.
Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2017; 7: CD004104.
Ambrosino N, Foglio K, Rubini F, Clini E, Nava S, Vitacca M. Non-invasive mechanical ventilation in acute respiratory failure due to chronic obstructive pulmonary disease: correlates for success. Thorax 1995; 50: 755-7.
Woodcock A, Boucot I, Leather DA, Crawford J, Collier S, Bakerly N, Hilton E, Vestbo J. Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. Eur. Respir. J. 2018; 51: 1701531.

Auteurs

Steven McKinstry (S)

Medical Research Institute of New Zealand, Wellington, New Zealand.
Victoria University of Wellington, Wellington, New Zealand.
Capital and Coast District Health Board, Wellington, New Zealand.

Joseph Singer (J)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Jan Pieter Baarsma (JP)

Medical Research Institute of New Zealand, Wellington, New Zealand.
University of Groningen, Groningen, The Netherlands.

Mark Weatherall (M)

Capital and Coast District Health Board, Wellington, New Zealand.
University of Otago Wellington, Wellington, New Zealand.

Richard Beasley (R)

Medical Research Institute of New Zealand, Wellington, New Zealand.
Victoria University of Wellington, Wellington, New Zealand.
Capital and Coast District Health Board, Wellington, New Zealand.

James Fingleton (J)

Medical Research Institute of New Zealand, Wellington, New Zealand.
Victoria University of Wellington, Wellington, New Zealand.
Capital and Coast District Health Board, Wellington, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH